ROLE OF CARDIAC MARKERS IN CHRONIC RENAL FAILURE PATIENTS.
-
Published:2020-11-01
Issue:
Volume:
Page:81-82
-
ISSN:
-
Container-title:INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH
-
language:en
-
Short-container-title:ijsr
Author:
Thanna Ramesh Chandra1, Agarwal B K2, Romday Rakesh3, Sharma Neha4
Affiliation:
1. Amaltas Institute Of Medical Sciences. 2. Professor of Biochemistry& PG director, index medical college and hospital and research centre, Indore, (M.P.) 3. Professor Of Medicine , Amaltas Institute Of Medical Sciences, Dewas, M.P. 4. Associate professor, Biochemistry, Geetanjali medical college and Hospital Udaipur, Rajasthan, India.
Abstract
Introduction: Cardiovascular diseases (CVD) are known as important reasons of the increased morbidity and mortality observed in patients with chronic renal failure (CRF). The association of serum Interlukin-6 , homocysteine as well as other cardiovascular risk factors in relation to existence and cause of CVD were investigated.
Method: In this study 200 CRF patients were recruited and further stratified into group with Male and Female as case groups. Those without renal failure were assigned as control group (n=200).
Results: The patients with CRF showed a significant increase in plasma levels of Cpk-MB homocysteine and C-reactive protein (CRP) compared to control. The positive association were observed between homocysteine, Urea and Hs-CRP, IL_6 . It shows a significant Association of parameters in CRF .
Conclusion: The results demonstrated elevation in plasma values IL-6 , homocysteine and HS-CRP in patients with CRF . However, these modifications may be lead to atherosclerosis and consequence CVD event. These parameters may be important with respect to the high morbidity and mortality of CVD found in patients with CRF.
Publisher
World Wide Journals
Reference15 articles.
1. Mason NA, Baille GR, Satayathum S, et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2005;45:119e26. 2. Wilson PWF, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837e47. 3. Rattazzi, M., Puato, M., Faggin, E., Bertipaglia, B., Grego, F & Pauletto P. (2003). New markers of accelerated atherosclerosis in end-stage renal disease. Journal of Nephrology, 16, 11-20. 4. Mallamaci, F., Zoccali, C., Tripepi, G., Fermo, I., Benedetto, FA., Cataliotti, A., Malatino, LS., Bellanuova I & Soldarini, A. (2002). Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int, 61, 609-614. 5. Kronenberg, F., Neyer, U., Lhotta, K.., Trenkwalder, E., Auinger, M., Pribasnig, A,, Meisl, T., Konig, P & Dieplinger, H. (1999). The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in haemodialysis patients: a prospective follow-up. J Am Soc Nephrol, 10, 1027-1036.
|
|